

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Cholestech Corporation		06/26/2007	CORPORATION: CALIFORNIA

RECEIVING PARTY DATA

Name:	General Electric Capital Corporation, as Agent
Street Address:	2 Bethesda Metro Center, Suite 600
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20814
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 4

Property Type	Number	Word Mark
Registration Number:	1767348	CHOLESTECH
Registration Number:	2882423	CHOLESTECH GDX
Registration Number:	1705798	CHOLESTECH L D X
Registration Number:	1799242	

CORRESPONDENCE DATA

Fax Number: (212)230-7740

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 212-318-6556

Email: kathleenmangual@paulhastings.com

Correspondent Name: Kathleen Mangual

Address Line 1: c/o Paul Hastings, LLP

Address Line 2: 75 East 55th Street

Address Line 4: New York, NEW YORK 10022

ATTORNEY DOCKET NUMBER:	SECOND LIEN
NAME OF SUBMITTER:	Kathleen Mangual

TRADEMARK

900089582

REEL: 003641 FRAME: 0638

\$115.00 1767348

OP

Signature:	/s/ Kathleen Mangual
Date:	10/17/2007

 Date: | 10/17/2007 |

Total Attachments: 66

source=Cholestech Second Lien#page1.tif
source=Cholestech Second Lien#page2.tif
source=Cholestech Second Lien#page3.tif
source=Cholestech Second Lien#page4.tif
source=Cholestech Second Lien#page5.tif
source=Cholestech Second Lien#page6.tif
source=Cholestech Second Lien#page7.tif
source=Cholestech Second Lien#page8.tif
source=Cholestech Second Lien#page9.tif
source=Cholestech Second Lien#page10.tif
source=Cholestech Second Lien#page11.tif
source=Cholestech Second Lien#page12.tif
source=Cholestech Second Lien#page13.tif
source=Cholestech Second Lien#page14.tif
source=Cholestech Second Lien#page15.tif
source=Cholestech Second Lien#page16.tif
source=Cholestech Second Lien#page17.tif
source=Cholestech Second Lien#page18.tif
source=Cholestech Second Lien#page19.tif
source=Cholestech Second Lien#page20.tif
source=Cholestech Second Lien#page21.tif
source=Cholestech Second Lien#page22.tif
source=Cholestech Second Lien#page23.tif
source=Cholestech Second Lien#page24.tif
source=Cholestech Second Lien#page25.tif
source=Cholestech Second Lien#page26.tif
source=Cholestech Second Lien#page27.tif
source=Cholestech Second Lien#page28.tif
source=Cholestech Second Lien#page29.tif
source=Cholestech Second Lien#page30.tif
source=Cholestech Second Lien#page31.tif
source=Cholestech Second Lien#page32.tif
source=Cholestech Second Lien#page33.tif
source=Cholestech Second Lien#page34.tif
source=Cholestech Second Lien#page35.tif
source=Cholestech Second Lien#page36.tif
source=Cholestech Second Lien#page37.tif
source=Cholestech Second Lien#page38.tif
source=Cholestech Second Lien#page39.tif
source=Cholestech Second Lien#page40.tif
source=Cholestech Second Lien#page41.tif
source=Cholestech Second Lien#page42.tif
source=Cholestech Second Lien#page43.tif
source=Cholestech Second Lien#page44.tif
source=Cholestech Second Lien#page45.tif
source=Cholestech Second Lien#page46.tif
source=Cholestech Second Lien#page47.tif
source=Cholestech Second Lien#page48.tif
source=Cholestech Second Lien#page49.tif

source=Cholestech Second Lien#page50.tif
source=Cholestech Second Lien#page51.tif
source=Cholestech Second Lien#page52.tif
source=Cholestech Second Lien#page53.tif
source=Cholestech Second Lien#page54.tif
source=Cholestech Second Lien#page55.tif
source=Cholestech Second Lien#page56.tif
source=Cholestech Second Lien#page57.tif
source=Cholestech Second Lien#page58.tif
source=Cholestech Second Lien#page59.tif
source=Cholestech Second Lien#page60.tif
source=Cholestech Second Lien#page61.tif
source=Cholestech Second Lien#page62.tif
source=Cholestech Second Lien#page63.tif
source=Cholestech Second Lien#page64.tif
source=Cholestech Second Lien#page65.tif
source=Cholestech Second Lien#page66.tif

SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of June 26, 2007, is made by each of the entities listed on the signature pages hereof (each a "Grantor" and, collectively, the "Grantors"), in favor of General Electric Capital Corporation ("GE Capital"), as administrative agent and collateral agent (in such capacity, together with its successors and permitted assigns, the "Administrative Agent") for the Lenders and the L/C Issuers (as defined in the Second Lien Credit Agreement referred to below).

WITNESSETH:

WHEREAS, pursuant to the Second Lien Credit Agreement, dated as of June 26, 2007 (as amended, restated, supplemented or otherwise modified from time to time, the "Second Lien Credit Agreement"), among the Borrower, Holdings and the Lenders from time to time party thereto and Administrative Agent and the Lenders have severally agreed to make extensions of credit to the Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, each Grantor has agreed, pursuant to a Second Lien Guaranty and Security Agreement of dated as of June 26, 2007 herewith in favor of the Administrative Agent (the "Guaranty and Security Agreement"), to guarantee the Obligations (as defined in the Second Lien Credit Agreement) of the other Loan Parties; and

WHEREAS, all of the Grantors are party to the Guaranty and Security Agreement pursuant to which the Grantors are required to execute and deliver this Intellectual Property Security Agreement.

NOW, THEREFORE, in consideration of the premises and to induce the Lenders and the Administrative Agent to enter into the Second Lien Credit Agreement and to induce the Lenders to make or continue to make their respective extensions of credit to the Borrower thereunder, each Grantor hereby agrees with the Administrative Agent as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

Section 2. Grant of Security Interest in Intellectual Property Collateral. Each Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations on the terms set forth in the Loan Documents, hereby mortgages, pledges and hypothecates to the Administrative Agent, for the benefit of the Secured Parties, and grants to the Administrative Agent, for the benefit of the Secured Parties, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of such Grantor (the "Intellectual Property Collateral"):

(a) Copyrights.

(i) all of its Copyrights and registrations and applications for registration thereof and all registered IP Licenses and applications therefor providing for the grant to such Grantor of any right under any Copyright, including, without limitation, those referred to on Schedule 1A hereto;

(ii) all renewals, reversions and extensions of the foregoing;

(iii) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

(b) Patents.

(i) all of its registered Patents and applications for registration therefor and all registered IP Licenses and applications thereof providing for the grant to such Grantor of any right under any Patent, including, without limitation, those referred to on Schedule 1B hereto;

(ii) all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(iii) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

(c) Trademarks.

(i) all of its Trademarks and applications for registration thereof and all registered IP Licenses and applications therefor providing for the grant to such Grantor of any right under any Trademark, including, without limitation, those referred to on Schedule 1C hereto;

(ii) all renewals and extensions of the foregoing;

(iii) all goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

(iv) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

Section 3. Guaranty and Security Agreement. The security interest granted pursuant to this Intellectual Property Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Guaranty and Security Agreement and each Grantor hereby acknowledges and agrees that the rights and remedies of the Administrative Agent with respect to the security interest in the Intellectual Property Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantor Remains Liable. Each Grantor hereby agrees that, anything herein to the contrary notwithstanding, such Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with such Grantor's Intellectual Property Collateral and IP Licenses subject to a security interest hereunder.

Section 5. Counterparts. This Intellectual Property Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.

Section 6. Governing Law. This Intellectual Property Security Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, each Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

IM US HOLDINGS, LLC
INVERNESS MEDICAL INNOVATIONS, INC.
ADVANTAGE DIAGNOSTICS CORPORATION
APPLIED BIOTECH, INC.
BINAX, INC.
FIRST CHECK DIAGNOSTICS CORP.
FOREFRONT DIAGNOSTICS, INC.
INCA ACQUISITION, INC.
INNOVATIVE MOBILITY, LLC
INSTANT TECHNOLOGIES, INC.
INVERNESS MEDICAL – BIOSTAR, INC.
INVERNESS MEDICAL INTERNATIONAL HOLDING CORP.
INVERNESS MEDICAL INTERNATIONAL HOLDING CORP. II
INNOVATIONS RESEARCH, LLC
INVERNESS MEDICAL, LLC
ISCHEMIA TECHNOLOGIES, INC.
IVC INDUSTRIES, INC.
INNOVACON, INC.
OSTEX INTERNATIONAL, INC.
QUALITY ASSURED SERVICES, INC.
SELF CARE TECHNOLOGY, INC.
SPDH, INC.
UNIPATH ONLINE, INC.
WAMPOLE LABORATORIES, LLC, as Grantors

Approved
As To Form


Legal Department

By: _____
Name: David Teitel

Title: President, Chief Financial Officer & Treasurer,
Vice President, Finance, Vice President, Vice
President, Finance, Vice President, Finance,
Vice President, Treasurer, Chief Financial
Officer, Vice President, Finance, Vice President,
Finance, President, President, Vice
President, Finance, Vice President, Finance,
Vice President, Finance, Vice President,
Finance, Vice President, Finance, Vice
President, Finance, Vice President, Finance,
Vice President, Finance, Vice President,
President, Finance, Chief Financial Officer, Vice
President, Finance, President, Vice
President, Vice President

[SIGNATURE PAGE TO SECOND LIEN IP SECURITY AGREEMENT]


LEGAL_US_E # 75504436

TRADEMARK
REEL: 003641 FRAME: 0644

ACCEPTED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION,
as Administrative Agent

By:



Name:

Title:

Andrew D Moore
Duly Authorized Signatory

[SIGNATURE PAGE TO SECOND LIEN IP SECURITY AGREEMENT]

LEGAL_US_E # 75504436

TRADEMARK
REEL: 003641 FRAME: 0645

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

A. REGISTERED COPYRIGHTS

None.

B. COPYRIGHT APPLICATIONS

None.

C. REGISTERED IP LICENSES AND ANY APPLICATIONS THEREFOR

None.

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

A. REGISTERED PATENTS

[Include Owner, Registration Number and Date]

B. PATENT APPLICATIONS

[Include Owner, Application Number and Date]

C. REGISTERED IP LICENSES AND ANY APPLICATIONS THEREFOR

[Include complete legal description of agreement (name of agreement, parties and date)]

Filing Number	Country	Filing date	Filing number	Grant date	Grant number	List of Owners or Assignees
IM0009	AT	19/MAR/2004	GM0005/2004	19/MAR/2014	19/MAR/2024	Advantage Diagnostics Corporation
IM0089	AU	19/MAR/2004	2004254558	19/MAR/2014	19/MAR/2024	Advantage Diagnostics Corporation
IM0089	BR	19/MAR/2004	PI0411059-5	19/MAR/2014	19/MAR/2024	Advantage Diagnostics Corporation
IM0089	CA	19/MAR/2004	2528108	19/MAR/2014	19/MAR/2024	Advantage Diagnostics Corporation
IM0089	CN	19/MAR/2004	2004480016772.7	10/APR/2006	16422	Advantage Diagnostics Corporation
IM0089	CZ	19/MAR/2004	2005-17219	06/APR/2006	212004000032.5	Advantage Diagnostics Corporation
IM0089	DE	19/MAR/2004	212004000032.5	13/APR/2007	DK200500290	Advantage Diagnostics Corporation
IM0089	DK	19/MAR/2004	BA200500290	04785762.6		Advantage Diagnostics Corporation
IM0089	EP	19/MAR/2004	06108552.1			Advantage Diagnostics Corporation
IM0089	HK	19/MAR/2004	06108524.8			Advantage Diagnostics Corporation
IM0089	JP	19/MAR/2004	20-2005-700007			Advantage Diagnostics Corporation
IM0089	KR	19/MAR/2004	PAJU2005/000303			Advantage Diagnostics Corporation
IM0089	MX	19/MAR/2004				Advantage Diagnostics Corporation
IM0089	PT	19/MAR/2004	2005003732			Advantage Diagnostics Corporation
IM0089	RU	19/MAR/2004	200512138919			Advantage Diagnostics Corporation
IM0089	US	19/MAR/2004	200512158919	15/JAN/2007	19871	Advantage Diagnostics Corporation
IM0089	US	06/JUN/2003	10456777.1	27/NOV/2006	58717	Advantage Diagnostics Corporation
AB0065	CA	23/JUL/2002	2455404	2005/12/01		Applied Biotech, Inc.
IM0079	US	02/JUN/2003	1045333.17	22/AUG/2000	6106732	Applied Biotech, Inc.
BNX0001	US	16/APR/1988	0910600885	15/APR/2003	6546309	Binax, Inc.
ENX0002	US	19/MAR/1993	09146777	30/JAN/2003	753633	Binax, Inc.
ENX0003	AU	25/AUG/1999	55933/99	17/OCT/2006	2342141	Binax, Inc.
ENX0003	CA	25/AUG/1999	2342141	28/JAN/2004	39810035.8	Binax, Inc.
ENX0003	CN	25/AUG/1999	99810035.8	03/JAN/2007	1107773	Binax, Inc.
ENX0003	EP	25/AUG/1999	99843394.17			Binax, Inc.
BNX0003	JP	25/AUG/1999	2000-565904	03/APR/2007	244714	Binax, Inc.
BNX0003	NX	25/AUG/1999	PA/001/002057			Binax, Inc.
BNX0003	US	09/139720		20/APR/2005	E283457	Binax, Inc.
BNX0004	AT	20/SEP/1999	99948305.0	24/JUL/2003	759229	Binax, Inc.
BNX0004	AU	20/SEP/1999	6151379	20/APR/2005	1113817	Binax, Inc.
BNX0004	BE	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	CA	20/SEP/1899	23427783	20/APR/2005	1113817	Binax, Inc.
BNX0004	CH	20/SEP/1999	99948305.0	17/AUG/2005	99811042.6	Binax, Inc.
BNX0004	CN	20/SEP/1999	99811042.6	20/APR/2005	1113817	Binax, Inc.
BNX0004	DE	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	DK	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	EP	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	ES	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	FI	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	FR	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	GB	20/SEP/1998	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	IE	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	IT	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	MX	20/SEP/1999	2000-573764	17/NOV/2005	232213	Binax, Inc.
BNX0004	NL	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	PT	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.

SE	US	BNX0004	20/SEP/1999	99848305.0	20/APR/2005	1113817	Binax, Inc.
		BNX0004	16/SEP/1999	091397110	30/NOV/2004	6824997	Binax, Inc.
		BNX0005	19/NOV/1999	091443211	21/APR/2004	6721073	Binax, Inc.
		BNX0006	11/DEC/2000	24283101	61/MAR/2006	783777	Binax, Inc.
	AU	BNX0006	11/DEC/2000	2393628			Binax, Inc.
	CA	BNX0006	EP	11/DEC/2000	00988037.8		Binax, Inc.
	US	BNX0006	US	10/DEC/1999	091458998	01/SEP/2005	2001241867
	AU	BNX0007	AU	01/MAR/2001	2001241867		Binax, Inc.
	CA	BNX0007	CA	19/AUG/2002	2427693		Binax, Inc.
	EP	BNX0007	EP	01/MAR/2001	01913177.0		Binax, Inc.
	JP	BNX0007	JP	01/MAR/2001	2001-563134		Binax, Inc.
	US	BNX0007	US	01/MAR/2000	091518195	15/JAN/2022	01/MAR/2021
	US	BNX0008	US	15/JAN/2002	101044920	15/JAN/2022	19/AUG/2022
	US	BNX0008	US	07/DEC/2005	11295486	27/FEB/2022	01/MAR/2021
	US	BNX0009	US	27/FEB/2002	101083476	24/FEB/2024	01/MAR/2021
	US	BNX0009	AU	24/FEB/2004	2004216189	24/FEB/2024	01/MAR/2020
	AU	BNX0009	CA	24/FEB/2004	2516546	24/FEB/2024	01/MAR/2021
	CN	BNX0011	CN	24/FEB/2004	20048006045.4	24/FEB/2024	01/MAR/2021
	EP	BNX0011	EP	24/FEB/2004	04714110.6	24/FEB/2024	01/MAR/2021
	HK	BNX0011	HK	24/FEB/2004	06105886.0	24/FEB/2024	01/MAR/2021
	JP	BNX0011	JP	24/FEB/2004	2006-503610	24/FEB/2023	01/MAR/2021
	US	BNX0011	US	24/APR/2004	10774155	29/JUL/2025	01/MAR/2025
	CN	BNX0012	CN	29/JUL/2005	200510084709.5	16/SEP/2019	01/MAR/2025
	US	BNX0012	US	16/NOV/2004	10989050	16/SEP/2019	01/MAR/2025
	US	BNX0012	US	23/MAY/2007	11740736	08/DEC/2007	01/AUG/2007
	US	BNX0015	US	08/DEC/2006	60/1073865	08/AUG/2007	01/MAR/2025
	US	BNX0016	US	08/AUG/2006	60/8566200	08/AUG/2007	01/MAR/2025
	CN	BNX0018	CN	01/MAR/2005	200586013456.1	26/NOV/2023	01/MAR/2025
	EP	BNX0018	EP	01/MAR/2005	05724003.8	26/NOV/2023	01/MAR/2025
	AU	BNX0019	AU	26/NOV/2003	2003295951	26/NOV/2023	01/MAR/2025
	CA	BNX0019	CA	26/NOV/2003	2541135	26/NOV/2023	01/MAR/2025
	CN	BNX0019	CN	26/NOV/2003	200380110715.2	26/NOV/2023	01/MAR/2025
	EP	BNX0019	EP	26/NOV/2003	037877165.0	26/NOV/2023	01/MAR/2025
	IN	BNX0019	IN	26/NOV/2003	17761/KOLNP/2006	26/NOV/2023	01/MAR/2025
	JP	BNX0019	JP	26/NOV/2003	2005-512287	26/NOV/2023	01/MAR/2025
	NZ	BNX0019	NZ	26/NOV/2003	PCT/US2003/037787	26/NOV/2023	01/MAR/2025
	US	BNX0019	US	16/NOV/2004	10785973	17/FEB/2025	01/MAR/2025
	CN	BNX0020	CN	17/FEB/2005	200580009058.1	17/FEB/2025	01/MAR/2025
	EP	BNX0020	EP	17/FEB/2005	056073858.5	17/FEB/2024	01/MAR/2025
	US	BNX0020	US	17/FEB/2005	111062211	17/FEB/2025	01/MAR/2025
	CN	BNX0021	CN	17/FEB/2005	200580010581.6	17/FEB/2025	01/MAR/2025
	EP	BNX0021	EP	17/FEB/2005	05723144.1	17/FEB/2025	01/MAR/2025
	IN	BNX0021	IN	17/FEB/2005	PCT/US2005/004896	17/FEB/2025	01/MAR/2025
	JP	BNX0021	JP	17/FEB/2005	2006-554175	17/FEB/2024	01/MAR/2025
	US	BNX0021	US	17/FEB/2005	111060113	17/FEB/2025	01/MAR/2025
	US	BNX0021	US	17/FEB/2005	111060113	06/OCT/2025	01/MAR/2025
	CN	BNX0022	CN	06/OCT/2005	PCT/US2005/035957		

BNX0022	EP	06/OCT/2005	PCT/US2005035967	06/OCT/2025
BNX0022	IN	06/OCT/2005	PCT/US2005035967	06/OCT/2025
BNX0022	JP	06/OCT/2005	PCT/US2005035967	06/OCT/2024
BNX0022	US	06/OCT/2005	11/24/4996	06/OCT/2007
BNX0022	US	06/OCT/2006	6/18/73741	05/JAN/2008
BNX0025	EP	06/JAN/2007	60/678750	20/OCT/2007
BNX0027	US	06/JAN/2007	60/855284	17/JAN/2008
BNX0028	US	20/OCT/2006	60/855284	10/APR/2008
BNX0029	US	11/JAN/2007	60/886791	02/SEP/2023
BNX0033	US	10/APR/2007	60/910904	22/MAY/2021
BNX0023	US	02/SEP/2003	10/658321	29/MAR/2022
A010006	CA	22/MAY/2001	24/09151	07/DEC/2020
A010007	CA	29/MAR/2002	24/4077	07/DEC/2020
BST0001	AU	07/DEC/2000	20/750101	07/DEC/2020
BST0001	CN	07/DEC/2000	00B17003.7	07/DEC/2020
BST0001	DE	07/DEC/2000	00B17003.7	07/DEC/2020
BST0001	EP	07/DEC/2000	00984071.1	07/DEC/2020
BST0001	FR	07/DEC/2000	00984071.1	07/DEC/2020
BST0001	GB	07/DEC/2000	00984071.1	07/DEC/2020
BST0001	JP	07/DEC/2000	2001-545519	07/DEC/2020
BST0001	KR	07/DEC/2000	2002-7007547	07/MAR/2021
BST0001	TV	07/MAR/2001	89126738	14/DEC/2019
BST0001	US	14/DEC/2000	09/737635	14/DEC/2019
BST0001	US	15/APR/2002	10/123750	09/JAN/2021
BST0001	TV	09/JAN/2001	69115794	20/MAR/2011
BST0002	DE	20/MAR/1991	91910056.0	20/MAR/2011
BST0004	EP	20/MAR/1991	91910056.0	20/MAR/2011
BST0004	ES	20/MAR/1991	91910056.0	20/MAR/2011
BST0004	FR	20/MAR/1991	91910056.0	20/MAR/2011
BST0004	GB	20/MAR/1991	91910056.0	20/MAR/2011
BST0004	HK	20/MAR/1991	97102308.7	20/MAR/2011
BST0004	IT	20/MAR/1991	97101991	20/MAR/2011
BST0004	JP	20/MAR/1991	97101991	20/MAR/2011
BST0004	DE	18/SEP/1990	90914615.1	18/SEP/2010
BST0005	EP	18/SEP/1990	90914615.1	18/SEP/2010
BST0005	FR	18/SEP/1990	90914615.1	18/SEP/2010
BST0005	GB	18/SEP/1990	90914615.1	18/SEP/2010
BST0005	HK	18/SEP/1990	90914615.1	18/SEP/2010
BST0005	IT	18/SEP/1990	90914615.1	18/SEP/2010
BST0005	JP	18/SEP/1990	2-513789	21/NOV/2012
BST0005	JP	18/SEP/1990	10-5911	28/MAR/2015
BST0005	US	31/JUL/1992	07/923304	11/FEB/2012
BST0005	US	28/MAR/1995	08/412600	11/FEB/2012
BST0005	DE	11/FEB/1992	92906299.0	11/FEB/2012
BST0005	EP	11/FEB/1992	92906299.0	11/FEB/2012
BST0006	ES	11/FEB/1992	92906299.0	11/FEB/2012
BST0006	FR	11/FEB/1992	92906299.0	11/FEB/2012
BST0006	GB	11/FEB/1992	92906299.0	11/FEB/2012
BST0006	HK	11/FEB/1992	98100895.9	11/FEB/2012

TRADEMARK
REEL: 003641 FRAME: 0650

IT	11/FEB/1992	92906299.0	24/JUL/2002	0524301	Inverness Medical - Biostar Inc.
JP	11/FEB/1992	50573992	28/JUL/2006	3833507	Inverness Medical - Biostar Inc.
JP	16/SEP/2003	2003-323351	27/AUG/1996	5550663	Inverness Medical - Biostar Inc.
US	10/JUN/1993	08/076347	25/NOV/1996	69227855.6	Inverness Medical - Biostar Inc.
DE	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.
EP	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.
ES	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.
FR	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.
GB	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.
HK	11/FEB/1992	98100899.5	24/MAR/2000	1001890	Inverness Medical - Biostar Inc.
IT	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.
BE	01/OCT/1991	91308968.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
DE	01/OCT/1991	91308968.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
EP	01/OCT/1991	91308968.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
ES	01/OCT/1991	91308968.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
FR	01/OCT/1991	91308968.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
GB	01/OCT/1991	91308968.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
HK	01/OCT/1991	91308968.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
JP	24/SEP/1992	19860998	02/OCT/1998	2834950	Inverness Medical - Biostar Inc.
JP	24/SEP/1992	25455282	09/JAN/1996	5482530	Inverness Medical - Biostar Inc.
US	10/JUN/1993	08/076320	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.
US	17/APR/1995	08/04035656	24/APR/1998	1000771	Inverness Medical - Biostar Inc.
US	31/MAY/1995	08/456040	09/SEP/2000	3107787	Inverness Medical - Biostar Inc.
US	31/MAY/1995	08/455652	02/OCT/1998	2834950	Inverness Medical - Biostar Inc.
US	10/JUN/1993	08/076719	23/MAY/1995	5418136	Inverness Medical - Biostar Inc.
US	10/JUN/1993	01/108521.4	10/JUN/1993	1126278	Inverness Medical - Biosstar Inc.
EP	10/JUN/1993	93915941.7	27/SEP/1999	5955377	Inverness Medical - Biosstar Inc.
EP	10/JUN/1993	05027236.8	13/MAY/1997	5629214	Inverness Medical - Biosstar Inc.
GB	10/JUN/1993	93915941.7	09/FEB/1999	5869272	Inverness Medical - Biosstar Inc.
GB	10/JUN/1993	01/108521.4	23/MAY/2007	1126278	Inverness Medical - Biosstar Inc.
HK	10/JUN/1993	93915941.7	14/DEC/2005	0727038	Inverness Medical - Biosstar Inc.
JP	10/JUN/1993	05027236.8	23/MAY/2007	1126278	Inverness Medical - Biosstar Inc.
JP	10/JUN/1993	01/108521.4	13/OCT/2006	1003304	Inverness Medical - Biosstar Inc.
JP	2001-236593	9810253.0	01/AUG/2003	3456984	Inverness Medical - Biosstar Inc.
JP	2001-236166	00010000	26/DEC/2003	3506703	Inverness Medical - Biosstar Inc.
JP	2001-236411	1984-505280	27/FEB/1996	5494829	Inverness Medical - Biosstar Inc.
JP	2001-236186	10/JUN/1993	20/MAY/1987	6631171	Inverness Medical - Biosstar Inc.
JP	2001-236186	10/JUN/1993	20/MAY/1987	6631171	Inverness Medical - Biosstar Inc.
JP	2001-236186	03/AUG/2001	03/AUG/2001	6060237	Inverness Medical - Biosstar Inc.
JP	03/AUG/2001	2001-236186	21/OCT/1999	6355428	Inverness Medical - Biosstar Inc.
JP	03/AUG/2001	2001-236186	09/425072	31/AUG/2004	Inverness Medical - Biosstar Inc.
JP	03/AUG/2001	2001-236186	18/OCT/2001	08/082658	Inverness Medical - Biosstar Inc.
JP	10/JUN/1993	08/075348	10/JUN/1993	03/SEP/1998	Inverness Medical - Biosstar Inc.
JP	10/JUN/1993	08/075348	10/JUN/1993	30/JUL/1996	Inverness Medical - Biosstar Inc.
JP	10/JUN/1993	08/075348	10/JUN/1993	02/DEC/2005	Inverness Medical - Biosstar Inc.
DE	02/DEC/1984	84306983.5	15/JUN/2005	69434406.0	Inverness Medical - Biosstar Inc.

EP	02/DEC/1994	94308983.9	15/JUN/2005	0659437	Inverness Medical - Biostar Inc.
ES	02/DEC/1994	94308983.9	16/JUN/2005	0659437	Inverness Medical - Biostar Inc.
FR	02/DEC/1994	94308983.9	16/JUN/2005	0659437	Inverness Medical - Biostar Inc.
GB	02/DEC/1994	94308983.9	15/JUN/2005	0659437	Inverness Medical - Biostar Inc.
HK	02/DEC/1994	98100898.6	23/SEP/2005	1001885	Inverness Medical - Biostar Inc.
IT	02/DEC/1994	94308983.9	15/JUN/2005	0659437	Inverness Medical - Biostar Inc.
US	03/DEC/1993	08/162401	27/FEB/1996	5494861	Inverness Medical - Biostar Inc.
AU	21/JUN/1999	49603199	26/SEP/2002	7479854	Inverness Medical - Biostar Inc.
CA	21/JUN/1999	2334584	03/MAY/2005	2334584	Inverness Medical - Biostar Inc.
CN	21/JUN/1999	99806819.5	07/APR/2004	99806819.5	Inverness Medical - Biostar Inc.
DE	21/JUN/1999	998033568.0	12/NOV/2003	1089800	Inverness Medical - Biostar Inc.
EP	21/JUN/1999	998033568.0	12/NOV/2003	1089800	Inverness Medical - Biostar Inc.
ES	21/JUN/1999	98833568.0	12/NOV/2003	1089800	Inverness Medical - Biostar Inc.
FR	21/JUN/1999	998033568.0	12/NOV/2003	1089800	Inverness Medical - Biostar Inc.
GB	21/JUN/1999	998033568.0	12/NOV/2003	1089800	Inverness Medical - Biostar Inc.
HK	21/JUN/1999	01107099.4	30/SEP/2004	1036236	Inverness Medical - Biostar Inc.
IN	21/JUN/1999	IN/PC172001/000662	12/NOV/2003	1089800	Inverness Medical - Biostar Inc.
IT	21/JUN/1999	998033568.0	12/NOV/2003	1089800	Inverness Medical - Biostar Inc.
JP	21/JUN/1999	2004-297857	16/FEB/2007	3916869	Inverness Medical - Biostar Inc.
MY	22/JUN/1999	P19902560	28/JAN/2006	121411A	Inverness Medical - Biostar Inc.
SG	21/JUN/1999	2000007494.8	30/JUN/2003	78192	Inverness Medical - Biostar Inc.
TW	24/JUN/1999	88110661	20/FEB/2001	N-121230	Inverness Medical - Biostar Inc.
US	28/JUN/1998	09/105309	18/JUL/2000	6090572	Inverness Medical - Biostar Inc.
US	17/JUL/2000	09167394	27/MAR/2001	6207445	Inverness Medical - Biostar Inc.
AU	06/MAR/2000	3727100	20/AUG/2004	772685	Inverness Medical - Biostar Inc.
CA	06/MAR/2000	2366307			Inverness Medical - Biostar Inc.
CN	06/MAR/2000	00805077.5			Inverness Medical - Biostar Inc.
EP	06/MAR/2000	00816114.2			Inverness Medical - Biostar Inc.
HK	06/MAR/2000	02104875.0			Inverness Medical - Biostar Inc.
IN	06/MAR/2000	IN/PC172001/000958	02/JUN/2006	199289	Inverness Medical - Biostar Inc.
JP	06/MAR/2000	2000-605247	19/JAN/2007	0674525	Inverness Medical - Biostar Inc.
KR	06/MAR/2000	10-2001-7011848	28/NOV/2003	83390	Inverness Medical - Biostar Inc.
SG	06/MAR/2000	200105414.7	11/DEC/2001	N-146428	Inverness Medical - Biostar Inc.
TW	06/APR/2000	89104986	18/MAR/1999	09/227641	Inverness Medical - Biostar Inc.
US	12/JUL/2001	09/905146	03/AUG/2004	6770447	Inverness Medical - Biostar Inc.
CN	03/AUG/2000	00312202.4			Inverness Medical - Biostar Inc.
EP	03/AUG/2000	00552567.6			Inverness Medical - Biostar Inc.
JP	03/AUG/2000	2001-5159.8	30/JUN/2006	3823053	Inverness Medical - Biostar Inc.
JP	03/AUG/2000	2005-37398			Inverness Medical - Biostar Inc.
KR	03/AUG/2000	10-2002-701601	23/JAN/2007	0675696	Inverness Medical - Biostar Inc.
TW	26/SEP/2000	89115787	11/JAN/2003	N-163801	Inverness Medical - Biostar Inc.
US	03/AUG/2000	09/632343	02/DEC/2003	6656426	Inverness Medical - Biostar Inc.
AU	20/OCT/1997	49129/97	09/AUG/2001	732463	Inverness Medical - Biostar Inc.
EP	20/OCT/1997	97911850.2			Inverness Medical - Biostar Inc.
HK	20/OCT/1997	99105268.6			Inverness Medical - Biostar Inc.
ID	20/OCT/1997	W-990278			
BST0023			22/DEC/2003	ID0012334	
BST0023					BST0027

BST0027	JP	20/OCT/1997	1998-520567	23/APR/2004	3547454	20/OCT/2017
BST0027	JP	20/OCT/1997	2003-3-12436	12/JUN/2007	3900289	30/OCT/2017
BST0027	TW	30/OCT/1997	86116219	21/JUN/2004	3900284	31/OCT/2016
BST0027	US	15/OCT/1997	08550963	26/DEC/2006	7153651	31/OCT/2016
BST0027	US	29/SEP/2000	091675518	23/AUG/2005	6933112	17/DEC/2019
BST0027	US	17/DEC/1999	21941/00	03/JUN/2004	770194	17/DEC/2019
BST0028	AU	17/DEC/1999	2007/10/13587.8			17/DEC/2019
BST0028	CN	17/DEC/1999	99815698.7			17/DEC/2019
BST0028	CN	17/DEC/1999	99815698.7			17/DEC/2019
BST0028	EP	17/DEC/1999	99966392.5			17/DEC/2019
BST0028	HK	17/DEC/1999	02/00371.7			17/DEC/2019
BST0028	IN	17/DEC/1999	281/DELNP/2006			17/DEC/2018
BST0028	JP	17/DEC/1999	2006-328455			26/JAN/2021
BST0028	MY	21/DEC/1999	P19905641	28/JAN/2006	MY-121411-A	17/DEC/2019
BST0028	SG	17/DEC/1999	200103852.0	29/AUG/2003	81760	17/DEC/2019
BST0028	TW	17/DEC/1999	88122288	11/DEC/2001	N-146232	29/DEC/2018
BST0028	US	29/DEC/1999	09/22/2000	09/22/2006	00811055.7	03/AUG/2020
BST0030	CN	03/AUG/2000	200510085540.5	24/MAR/2006		03/AUG/2020
BST0030	CN	03/AUG/2000	200510085540.5			03/AUG/2020
BST0030	EP	03/AUG/2000	09953853.9			03/AUG/2020
BST0030	IN	03/AUG/2000	IN/PCT/2002/00161			03/AUG/2020
BST0030	JP	03/AUG/2000	2004-219169	10/FEB/2005	3645523	03/AUG/2020
BST0030	JP	03/AUG/2000	2001-5415920			04/AUG/2020
BST0030	KR	03/AUG/2000	10-2002-701557			04/AUG/2020
BST0030	US	04/AUG/2000	096333036	19/NOV/2002	6463585	14/APR/2024
BST0030	CN	14/APR/2004	2004-80010302.1			14/APR/2024
BST0032	EP	14/APR/2004	04730150.7			14/APR/2024
BST0032	HK	14/APR/2004	06102354.0			14/APR/2024
BST0032	IN	14/APR/2004	3751/DELNP/2005			14/APR/2024
BST0032	JP	14/APR/2004	2006-510051			14/APR/2024
BST0032	KR	14/APR/2004	10-2005-70119594			16/APR/2023
BST0032	US	16/APR/2003	10/4/17883			08/JUL/2020
BST0032	ES	21/SEP/1998	146394	06/JUL/2000	146394	06/APR/2016
BST0029	JP	22/MAR/1989	11-025661	05/APR/2001	1110879	10/OCT/2014
BST0029	US	22/MAR/1989	29/102418	10/OCT/2000	D431867	02/OCT/2023
ISC0008	US	02/OCT/2003	10/679869			02/OCT/2023
ISC0008	US	02/OCT/2003	10/679869			02/OCT/2018
ISC0009	US	02/OCT/1998	09/185928	08/OCT/2002	64616875	02/OCT/2018
ISC0009	US	02/OCT/1998	09/165561	10/DEC/2002	6492179	10/JUL/2012
ISC0004	US	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISC0005	AT	10/JUL/1992	10006197	26/AUG/1999	705300	10/JUL/2012
ISC0005	AU	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISC0005	BE	10/JUL/1992	92915563.8	02/MAY/2001	P19206312.8	10/JUL/2012
ISC0005	BR	10/JUL/1992	P19206312.8			10/JUL/2012
ISC0005	CA	10/JUL/1992	2113266	10/JAN/2006	2/113266	10/JUL/2012
ISC0005	CH	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISC0005	DE	10/JUL/1992	92915563.8	09/MAR/2005	69233487.4	10/JUL/2012
ISC0005	DK	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISC0005	EP	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISC0005	EP	01/DEC/2003	03027486.4			

ES	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012	
FR	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012	
GB	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012	
GR	10/JUL/1992	92915563.8	09/MAR/2005	3053499	10/JUL/2012	
IE	24/JUL/1992	1992/2421	18/FEB/2006	84165	24/JUL/2012	
ISCO005	02/AUG/2005	2005/0515	09/MAR/2005	0596925	10/JUL/2012	
ISCG005	IT	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISCP005	JP	10/JUL/1992	50358183	01/JUN/2001	3194952	10/JUL/2012
ISCP005	KR	10/JUL/1992	700225/1994	23/OCT/1993	239447	10/JUL/2012
ISCP005	LU	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISCP005	MC	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISCP005	NL	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISCP005	NO	10/JUL/1992	1994/0256	16/DEC/2002	313500	14/APR/2014
ISCP005	PT	24/JUL/1992	100724	10/7/24	100724	16/JUL/2012
ISCP005	SE	10/JUL/1992	92915563.8	09/MAR/2005	0596925	16/JUL/2011
ISCP005	US	26/JUL/1991	077736583	13/JUL/1993	5227307	26/JUL/2011
ISCP005	US	12/FEB/1993	08016971	01/MAR/1994	5290519	01/OCT/2019
ISCP005	EP	01/OCT/1998	99950055.6	05/NOV/2002	6475743	02/OCT/2018
ISCP006	US	02/OCT/1998	09165961	04/AU/2006	707037	02/OCT/2018
ISCP006	US	29/MAR/2001	09/820416			02/OCT/2018
ISCP006	US	30/AUG/2002	10/232341			02/OCT/2018
ISCP006	US	31/JAN/2005	11/049320			30/MAY/2022
ISCP007	EP	30/MAY/2002	02734574.3			30/MAY/2022
ISCP007	US	30/MAY/2002	10/477384	27/MAY/2004	769727	01/OCT/2019
ISCP010	AU	01/OCT/1999	64095/99			01/OCT/2019
ISCP010	CA	01/OCT/1999	2344762			01/OCT/2019
ISCP010	EP	01/OCT/1999	9995/17/10.5			01/OCT/2019
ISCP010	JP	01/OCT/1999	2000-574907			01/OCT/2019
ISCP010	US	15/APR/2003	10/4/14489			01/OCT/2019
ISCP010	US	15/APR/2003	10/4/13832			01/OCT/2019
ISCP010	US	15/APR/2003	10/4/14386			01/OCT/2019
ISCP010	US	15/APR/2003	10/4/13831			02/OCT/2018
ISCP011	US	13/DEC/2002	10/3/19263			26/NOV/2022
ISCP011	US	12/JAN/2005	11/0337766			26/NOV/2022
ISCP012	AU	26/NOV/2002	2002352959			26/NOV/2022
ISCP012	CA	26/NOV/2002	2468236			26/NOV/2022
ISCP012	EP	26/NOV/2002	02739819.4			26/NOV/2022
ISCP012	JP	26/NOV/2002	2003-5477926			26/NOV/2022
ISCP012	US	01/MAY/2006	11/4/15929	20/JUN/2006	7063762	26/NOV/2021
ISCP012	AU	30/APR/2002	2002305335			30/APR/2022
ISCP013	CA	30/APR/2002	2446187			30/APR/2022
ISCP013	DE	30/APR/2002	02734148.6	27/DEC/2006	60217102.4	30/APR/2022
ISCP013	EP	30/APR/2002	02734148.6	27/DEC/2006	1392150	30/APR/2022
ISCP013	FR	30/APR/2002	02734148.6	27/DEC/2006	1392150	30/APR/2022
ISCP013	GB	30/APR/2002	02734148.6	27/DEC/2006	1392150	30/APR/2022
ISCP013	JP	30/APR/2002	2002-585861			04/MAY/2021
ISCP013	US	04/MAY/2001	091849956			

ISC0014	AU	29/APR/2002	2002308530	Ischemia Technologies, Inc.
ISC0014	CA	29/APR/2002	2446529	Ischemia Technologies, Inc.
ISC0014	EP	29/APR/2002	02769865.6	Ischemia Technologies, Inc.
ISC0014	JP	29/APR/2002	2002-585988	Ischemia Technologies, Inc.
ISC0014	US	01/MAY/2001	09/846411	01/MAY/2021
ISC0014	AU	05/MAY/2004	2004240557	05/MAY/2024
ISC0015	CA	05/MAY/2004	2524530	05/MAY/2024
ISC0015	CN	05/MAY/2004	200440013619.0	05/MAY/2024
ISC0015	EP	05/MAY/2004	04751679.4	05/MAY/2024
ISC0015	HK	05/MAY/2004	06110013.6	05/MAY/2024
ISC0015	IL	05/MAY/2004	171781	05/MAY/2024
ISC0015	IN	05/MAY/2004	21311KOLNP/2005	05/MAY/2024
ISC0015	JP	05/MAY/2004	2006-532878	05/MAY/2024
ISC0015	KR	05/MAY/2004	2005-7020921	05/MAY/2024
ISC0015	NZ	05/MAY/2004	543538	05/MAY/2024
ISC0015	SG	05/MAY/2004	200501034.7	14/MAY/2024
ISC0015	US	19/MAY/2003	10/441155	19/MAY/2023
ISC0015	US	22/DEC/2005	11/317631	23/JAN/2026
ISC0016	EP	23/JAN/2006	06719258.3	20/APR/2013
SELF0001	US	10/MAR/1996	29/034813	04/APR/2014
SELF0001	US	24/SEP/1996	094066	04/APR/2000
				Selfcare Selfcare

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

D. REGISTERED TRADEMARKS

[Include Owner, Registration Number and Date]

E. TRADEMARK APPLICATIONS

[Include Owner, Application Number and Date]

F. REGISTERED IP LICENSES AND ANY APPLICATIONS THEREFOR

[Include complete legal description of agreement (name of agreement, parties and date)]

WANTILES	Wanted Laboratories, LLC	JORDANIAS	05/15/1988	1487
WANTILES	Wanted Laboratories, LLC	JASABA	05/04/1991	17020
WANTILES (AND DESIGN)	Wanted Laboratories, LLC	POCETAL	05/22/1997	183140
WANTILES (AND DESIGN)	Wanted Laboratories, LLC	SPAIN	05/22/1997	183137
WANTILES (AND DESIGN)	Wanted Laboratories, LLC	COSTA RICA	05/15/1994	1357
WANTILES (AND DESIGN)	Wanted Laboratories, LLC	PANAMA	05/15/1994	1358
WANTILES (AND DESIGN)	Wanted Laboratories, LLC	CHILE	05/15/1994	1359
WANTILES (AND DESIGN)	Wanted Laboratories, LLC	PERU	05/15/1994	1360
WANTILES (AND DESIGN)	Wanted Laboratories, LLC	UNITED KINGDOM	05/15/1994	1361
WANTILES (AND DESIGN)	Wanted Laboratories, LLC	UNITED STATES OF AMERICA	05/15/1994	1362
WANTILES (AND DESIGN)	Wanted Laboratories, LLC	UNITED STATES OF AMERICA	05/15/1994	1363
WANTILES (AND DESIGN)	Wanted Laboratories, LLC	UNITED STATES OF AMERICA	05/15/1994	1364
WANTILES (AND DESIGN)	Wanted Laboratories, LLC	UNITED STATES OF AMERICA	05/15/1994	1365
WE WANTED LABORATORIES (AND DESIGN)	WE WANTED LABORATORIES (AND DESIGN)	URUGUAY	05/15/1994	1366
WE WANTED LABORATORIES (AND DESIGN)	WE WANTED LABORATORIES (AND DESIGN)	VENEZUELA	05/15/1994	1367


**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of June 29, 2007, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedules IA, IB and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedules IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

BIOSITE INCORPORATED

By: 
Name: David Teitel
Title: Treasurer

Approved
As To Form


Legal Department

[SIGNATURE PAGE TO SECOND LIEN COUNTERPART TO IP SECURITY AGREEMENT]

LEGAL_US_E # 75512367

TRADEMARK
REEL: 003641 FRAME: 0666

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Biosite Incorporated as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of June 29, 2007 and give effect to, and contain data relating to, the acquisition by a wholly-owned subsidiary of Inverness Medical Innovations, Inc. of the capital stock of Biosite Incorporated only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None.

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

See attached list of patents.

Title	Inventor	Application No. Filing Date	Patent No. Issue Date
Polypeptides Related to Natriuretic Peptides and Methods of their Identification and Use	Buechler, Kenneth F. Fung, Eric Thomas Yip, Tai-Tung	2522709 04/19/2004	
Polypeptides Related to Natriuretic Peptides and Methods of Their Identification and Use	Buechler, Kenneth F. Fung, Eric Thomas Yip, Tai-Tung	10/827919 04/19/2004	
Human Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	09/453234 12/01/1999	6794132 09/21/2004
Human Antibodies	Lonberg, Nils Buechler, Joe Gray, Jeff Valkirs, Gunars E.	10/111365 04/01/2002	7135287 11/14/2006
Human Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	11/521060 09/13/2006	
Human Antibodies as Diagnostic Reagents	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	09/456090 12/06/1999	6680209 01/20/2004
Human Antibodies as Diagnostic Reagents	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	10/149737 06/06/2002	7189515 03/13/2007
Assays and Kits for Detecting Analytes In the Presence of Cross-Reacting Substances	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	11/685068 03/12/2007	
Methods for Concentrating Ligands Using Magnetic Particles	Valkirs, Gunars E.	08/006341 01/19/1993	5914241 06/22/1999
Polyvalent Display Libraries	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	09/054918 04/03/1998	6348318 02/19/2002
Polyvalent Display Libraries	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	08/832985 04/04/1997	6057098 05/02/2000
Polyvalent Display Libraries	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	09/1563055 05/01/2000	6985986 01/17/2006

TRADEMARK

REEL: 003641 FRAME: 0670

Title	Inventor	Application No.	Patent No.
		Filing Date	Issue Date
Polyclonal Libraries	Gray, Jeff Buechler, Joe Valkirs, Gunars E.	08/835159 04/04/1997	6555310 04/29/2003
Diagnostic Tests and Kits for Clostridium Difficile	Valkirs, Gunars E.	08/832935 04/04/1997	5965375 10/12/1999
Diagnostic Tests and Kits for Clostridium Difficile	Valkirs, Gunars E.	09/363960 07/29/1999	6503722 01/07/2003
Recombinant Library Screening Methods	Dower, William J. Cwirka, Steven E.	07/517659 05/01/1990	5427908 06/27/1995
Recombinant Library Screening Methods	Dower, William J. Cwirka, Steven E.	08/376326 01/20/1995	5589717 12/03/1996
RECOMBINANT LIBRARY SCREENING METHODS	Dower, William J. Cwirka, Steven E.	08/450754 05/25/1995	
DIAGNOSTIC ASSAY FOR DETECTION OF CRYPTOSPORIDIUM PARVUM	Gray, Jeff Valkirs, Gunars E. Buechler, Joe	09/158180 09/21/1998	
Diagnostic Assays for Detection of Cryptosporidium Parvum	Gray, Jeff Valkirs, Gunars E. Buechler, Joe	09/877933 06/07/2001	7052858 05/30/2006
Diagnostic Assays for Detection of Giardia Lamblia	Buechler, Joe Govindaraj, Shanthi Gray, Jeff Valkirs, Gunars E.	10/155163 05/23/2002	6908739 06/21/2005
Diagnostic Assays for Detection of Entamoeba Histolytica	Valkirs, Gunars E. Buechler, Joe Gray, Jeff	09/158347 09/21/1998	6207395 03/27/2001
Chimeric Polyclonal Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	09/410903 10/02/1999	6420113 07/16/2002
Chimeric Polyclonal Antibodies	Buechler, Joe	10/193960 07/12/2002	
Use of a Tag to Enrich Polypeptides Libraries	Buechler, Joe Valkirs, Gunars Gray, Jeff	11/015628 12/16/2004	
Assays for Detection of Bacillus Anthracis	Lee, Bruce A. Flores, Becky M. Valkirs, Gunars E.	09/754947 01/04/2001	6828110 12/07/2004

Title	Inventor	Application No. Filing Date	Patent No. Issue Date
Assays for Detection of Bacillus Anthracis	Lee, Bruce A. Flores, Becky M.	10/890083 07/12/2004	
Methods for Detecting B. Anthracis Infection	Valkirs, Gunars E. Buechler, Kenneth F.	10/339744 01/08/2003	
Methods for Detecting B. Anthracis Infection	Valkirs, Gunars E. Buechler, Kenneth F.	10/447300 05/27/2003	
Compositions and Methods for Phage Display of Polypeptides	Gray, Jeff	11/198920	
Latent Protein C Assays and Their Uses for Diagnosis and/or Prognosis in Systemic Inflammatory Response Syndromes	Valkirs, Gunars E. Buechler, Joe	08/05/2005 11/614836 12/21/2006	
High Sensitivity Secretagogin Assays and Their Uses for Diagnosis and/or Prognosis	Buechler, Joe Nakamura, Kevin	11/654901 01/17/2007	

TITLE	INVENTORS	CNTRY	SERIAL NO./ FILING DATE	REG NO./ REG. DATE
Devices and Methods for Performing Receptor Binding Assays Using Magnetic Particles	John Michael Anderberg David M. Gregory	USA	60/834,073 07/28/2006	
Methods and Compositions For Monitoring And Risk Prediction in Cardiorenal Syndrome	Gunars Valkirs Paul H. McPherson	USA	60/859,137 11/14/2006	
Methods and compositions for monitoring and risk prediction in cardiorenal syndrome	Gunars Valkirs Paul H. McPherson	USA	60/891,342 02/23/2007	
Method and Compositions for Diagnosis and Prognosis of Renal Artery Stenosis	Gunars Valkirs Paul H. McPherson	USA	60/859,136 11/14/2006	

BIOSITE Case Listing

Country	Application Number	Application Date	Pated Number	Grant Date	Title
United States of America	11/1512743	8/29/2006			USE OF SOLUBLE FLT-1 AND ITS FRAGMENTS IN CARDIOVASCULAR CONDITIONS
United States of America	11/684498	3/9/2007			METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF DISEASES OF THE AORTA
United States of America	11/752135	5/22/2007			USE OF Natriuretic Peptides As Diagnostic And Prognostic Indicators In Vascular Diseases
United States of America	07/593378	10/10/1990	5091512	2/25/1992	Fibrinogen-specific monoclonal antibody
United States of America	07/364053	6/8/1989	5120834	6/9/1992	Fibrin-specific monoclonal antibody
United States of America	07/835800	2/14/1992	5223410	6/29/1993	Method for production of antibodies using an antigen-free animal
United States of America	07/295568	1/10/1989	5028535	7/2/1991	Threshold Ligand-Receptor Assay
United States of America	08/284035	8/1/1994	5679526	10/21/1997	Threshold Ligand-Receptor Assay
United States of America	08/871900	6/11/1987	5539272	8/17/1999	Non-Competitive Threshold Ligand-Receptor Assays
United States of America	08/458276	6/21/1995	5922615	7/13/1999	Device for Ligand Receptor Methods
United States of America	09/249321	2/11/1999	6297060	10/2/2001	Device for Ligand Receptor Methods
United States of America	07/463150	1/10/1990	5085391	2/18/1992	Threshold Ligand-Receptor Assay
United States of America	07/583046	9/14/1990	5143852	9/11/1992	Antibodies To Ligand Analogues And Their Utility In Ligand-Receptor Assays
United States of America	07/808515	12/16/1991	5233042	8/3/1993	Novel Cocaine Derivatives And Protein And Polypeptide Cocaine Derivative Conjugates And Labels
United States of America	07/864110	4/6/1992	5414085	5/9/1995	Novel Barbiturate Derivatives And Protein And Polypeptide Barbiturate Derivative Conjugates And Labels

BIOSITE Case Listing

Country	Application Number	Applied for Date	Patent No.	Grant Date	Title
United States of America	07/864106	4/6/1992	5470997	11/28/1995	AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864106	4/6/1992	5237057	8/17/1993	NOVEL TETRAHYDROCANNABINOL DERIVATIVES AND PROTEIN AND POLYPEPTIDE TETRAHYDROCANNABINOL DERIVATIVE CONJUGATES AND LABELS
United States of America	08/032598	3/17/1993	5302703	4/12/1994	TETRAHYDROCANNABINOL DERIVATIVES AND PROTEIN AND POLYPEPTIDE TETRAHYDROCANNABINOL DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864093	4/6/1992	5302715	4/12/1994	NOVEL BENZODIAZEPINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE BENZODIAZEPINE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864104	4/6/1992	5331109	7/19/1994	PHENCYCLIDINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE PHENCYCLIDINE DERIVATIVE CONJUGATES AND LABELS
United States of America	08/241061	5/11/1994	6777190	8/17/2004	CROSSTALK INHIBITORS AND THEIR USES
United States of America	08/101677	8/3/1993	5525524	6/11/1996	CROSSTALK INHIBITORS AND THEIR USES
United States of America	07/1887526	5/21/1992	5458852	10/17/1995	DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF A REAGENT WITHOUT MEMBRANES
United States of America	08/447895	5/23/1995	6019944	21/12/2000	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	08/447981	5/23/1995	58885527	3/23/1999	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/628041	3/27/1997	6156270	1/25/2000	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/902775	7/30/1997	6271040	8/7/2001	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/810569	3/3/1997	6143376	1/17/2000	NON-POROUS DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF REAGENTS
United States of America	09/613650	7/11/2000			DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	09/805653	3/13/2001	6767510	7/7/2004	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	09/982529	10/18/2001	69058882	6/14/2005	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	10/697351	10/29/2003			DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	10/792258	3/2/2004			DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	11/022297	12/22/2004			DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	08/416034		4/3/1995 5710256	1/20/1998	METHADONE DERIVATIVES AND PROTEIN AND POLYPEPTIDE METHADONE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/973997	11/9/1992	6037455	3/14/2000	PROPOXYPHENE DERIVATIVES AND PROTEIN AND POLYPEPTIDE PROPOXYPHENE DERIVATIVE CONJUGATES AND LABELS
United States of America	08/071203	6/1/1993	5480792	1/2/1996	ANTIBODIES TO COMPLEXES OF LIGAND RECEPTORS AND LIGANDS AND THEIR UTILITY IN LIGAND-RECEPTOR ASSAYS
United States of America	08/458901	6/2/1995	5985579	11/16/1999	ANTIBODIES TO COMPLEXES OF LIGAND RECEPTORS AND LIGANDS AND THEIR UTILITY IN LIGAND-RECEPTOR ASSAYS
United States of America	08/101782	8/3/1993	5851176	12/22/1998	CONJUGATES AND ASSAYS FOR SIMULTANEOUS DETECTION OF MULTIPLE LIGANDS
United States of America	08/311098	9/23/1994	5763189	6/3/1998	FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN MICROPARTICLES USING NOVEL COMPOUNDS
United States of America	08/409298	3/23/1995	6251687	6/26/2001	FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN PARTICLES USING NOVEL COMPOUNDS
United States of America	08/389969	2/15/1995	5610283	3/11/1997	OPIATE DERIVATIVES AND PROTEIN AND POLYPEPTIDE OPIATE DERIVATIVE CONJUGATION AND LABELS
United States of America	08/423582		4/18/1995 5795725	8/18/1998	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	08/633248	4/18/1996	6174686	1/16/2001	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	08/769077	12/18/1996	6627404	9/30/2003	METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	09/349194	7/7/1999	6939678	9/6/2005	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	09/425318	10/21/1999	6579687	6/17/2003	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	09/687051	10/12/2000	6591907	1/31/2006	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	10/459006	6/10/2003			METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	10/850954	5/21/2004			NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	11/673397	2/9/2007			METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	08/517949	8/22/1995	6803040	10/12/2004	DERIVATIVES OF TRICYCLIC ANTIDEPRESSANTS AND PROTEIN AND POLYPEPTIDE TRICYCLIC ANTIDEPRESSANT DERIVATIVE CONJUGATES AND LABELS

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	087/04804	8/26/1996	6391265	5/21/2002	DEVICES INCORPORATING FILTERS FOR FILTERING FLUID SAMPLES
United States of America	10/153423	5/21/2002			DEVICES FOR INCORPORATING FILTERS FOR FILTERING FLUID SAMPLES
United States of America	08/620597	3/22/1996	5824799	10/20/1998	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	09/776599	2/1/2001	7083984	8/1/2006	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	08/274534	7/12/1994	6238931	5/29/2001	FLUORESCENCE ENERGY TRANSFER AND PARTICLES
United States of America	09/066255	4/24/1998	6964844	11/15/2005	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	11/448613	6/6/2006			HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	08/749702	11/15/1996	6113855	9/5/2000	DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	09/612815	7/10/2000	6669907	12/30/2003	DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	10/746232	12/24/2003			DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	08/837309	4/9/1997	6544797	4/8/2003	COMPOSITIONS AND METHODS FOR INHIBITING LIGHT-INDUCED INACTIVATION OF BIOLOGICAL REAGENTS
United States of America	10/338182	17/2003			NOVEL COMPOSITIONS AND METHODS FOR INHIBITING LIGHT-INDUCED INACTIVATION OF BIOLOGICAL REAGENTS
United States of America	09/081722	5/13/1998	6670196	1/23/2003	RAPID EVALUATION OF THE RATIO OF BIOLOGICAL MOLECULES
United States of America	10/697356	10/29/2003	7202042	4/10/2007	RAPID EVALUATION OF THE RATIO OF BIOLOGICAL MOLECULES
United States of America	08/821888	3/21/1997	5947124	9/7/1999	DIAGNOSTIC FOR DETERMINING THE TIME OF A HEART ATTACK
United States of America	08/942370	10/21/1997	6106779	8/22/2000	ALYSIS CHAMBER FOR USE IN AN ASSAY DEVICE
United States of America	09/003066	1/5/1998	6074616	6/13/2000	MEDIA CARRIER FOR AN ASSAY DEVICE

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	09/545699	4/6/2000	6392994	5/21/2002	MEDIA CARRIER FOR AN ASSAY DEVICE
United States of America	07/299277	1/23/1989	5202234	4/13/1993	MYOCARDIAL INFARCTION ASSAY
United States of America	07/882299	5/13/1992	5326592	7/5/1994	FLUORESCENT MICROARTICLES WITH CONTROLLABLE ENHANCED STOKES SHIFT
United States of America	09/358130	7/20/1999	6302919	10/16/2001	REVERSE-FLOW CENTRIFUGAL FILTRATION METHOD
United States of America	11/204764	8/15/2005			USE OF A GLUTATHIONE PEROXIDASE 1 AS A MARKER IN CARDIOVASCULAR CONDITIONS
United States of America	09/003090	1/5/1998	6830731	12/14/2004	IMMUNOASSAY FLUOROMETER
United States of America	10/267232	10/8/2002			IMMUNOASSAY FLUOROMETER
United States of America	10/841274	5/7/2004			IMMUNOASSAY FLUOROMETER
United States of America	09/003065	1/5/1998	6194222	2/27/2001	METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS
United States of America	09/7712615	11/13/2000			METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS
United States of America	11/676032	2/16/2007			METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS
United States of America	08/993750	12/19/1997	6195521	12/15/2000	METHODS FOR THE RECOVERY AND MEASUREMENT OF TROPONIN COMPLEXES
United States of America	09/7835298	4/13/2001			USE OF B-TYPE Natriuretic Peptide AS A PROGNOSTIC INDICATOR IN ACUTE CORONARY SYNDROMES
United States of America	10/389720	3/13/2003			USE OF B-TYPE Natriuretic Peptide AS A PROGNOSTIC INDICATOR IN ACUTE CORONARY SYNDROMES
United States of America	10/225082	8/20/2002			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/371149	2/20/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF

BIOSITE Case Listing

Country	Patent Number	Application Date	Patent Number	Grant Date	Title
United States of America	10/673077	9/26/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/1714078	11/14/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHODS OF USE THEREOF
United States of America	10/8755800	6/23/2004			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/330696	12/27/2002			MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	10/728067	12/31/2003			USE OF THROMBUS PRECURSOR PROTEIN AND MONOCYTE CHEMOATTRACTANT PROTEIN AS DIAGNOSTIC AND PROGNOSTIC INDICATORS IN VASCULAR DISEASES
United States of America	10/952275	9/27/2004			METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF SEPSIS
United States of America	11/022552	12/23/2004			METHODS AND COMPOSITIONS FOR DETERMINING TREATMENT REGIMENS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	10/759216	1/20/2004			BIOMARKERS FOR SEPSIS
United States of America	11/1543312	10/31/2006			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	11/690767	3/23/2007			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	11/1770608	6/28/2007			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America					ARGININE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	10/139086	5/4/2002			DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROME AND METHODS OF USE THEREOF
United States of America	11/205571	8/17/2005			DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROME AND METHODS OF USE THEREOF
United States of America	10/331127	12/27/2002			METHOD AND SYSTEM FOR DISEASE DETECTION USING MARKER COMBINATIONS
United States of America	10/410572	4/8/2003			SYSTEM AND METHOD FOR IDENTIFYING A PANEL OF INDICATORS
United States of America	10/1603891	6/24/2003			(PROTEOME) MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	11/737621	4/19/2007			(PROTEOME) MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	10/419059	4/17/2003			POLYPEPTIDES RELATED TO Natriuretic Peptides AND METHODS OF THEIR IDENTIFICATION AND USE
United States of America	10/645874	8/20/2003			METHODS AND COMPOSITIONS FOR MEASURING BIOLOGICALLY ACTIVE Natriuretic Peptides AND FOR IMPROVING THEIR THERAPEUTIC POTENTIAL
United States of America	10/938760	9/9/2004			METHODS AND COMPOSITIONS FOR MEASURING Natriuretic Peptides AND USES THEREOF
United States of America	11/560425	11/16/2006			COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND MYOCARDIAL INFARCTION WITH DIPEPTIDYL PEPTIDASE INHIBITORS OR B TYPE Natriuretic Peptide ANALOGUES RESISTANT TO PROLYL-SPECIFIC DIPEPTIDYL DEGRADATION
United States of America	11/2222494		9/7/2005		METHODS AND COMPOSITIONS FOR MEASURING CANINE BNP AND USES THEREOF

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	10778919	2/12/2004	6887952	5/3/2005	N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	117080211	3/14/2005	6967107	11/22/2005	N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	11184746	7/19/2005			N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	11450150	6/9/2006			METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF VENOUS THROMBOEMBOLIC DISEASE

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

See attached list of trademarks.

COUNTRY	TRADEMARK	CLASS(ES)	APPL. NO. FILING DATE	REG NO. ISSUE DATE
US	AN UNFAIR ADVANTAGE	1, 42	75/609619 12/21/1998	2453707 05/22/2001
US	BIOSITE DISCOVERY AN UNFAIR ADVANTAGE & Design	1, 5, 42	75/655110 03/05/1999	2456330 05/29/2001
US	OMNICLONAL	1, 5	75/609841 12/21/1998	2476239 08/07/2001

MARK	COUNTRY	SERIAL NO. FILING DATE	REG. NO./ REG. DATE
MULTIMARKER INDEX	USA	78/574,678 02/24/2005	

TRADEMARK
REEL: 003641 FRAME: 0686

Biosite (U.S. only)

Docket Number	Country	Mark	Priority Status	Owner Name	Application Date	Registration Date	Registration Number
071949-4501	United States of America	IN TIME TO DECIDE	Registered	Biosite Inc	78/056518	4/3/2001	7/30/2002 2601205
071949-4601	United States of America	NEW DIMENSIONS IN DIAGNOSIS	Registered	Biosite Inc	78/072981	7/9/2001	8/26/2003 2757467
071949-4701	United States of America	ASCEND MULTIMUNOASSAY	Registered	Biosite Inc	74/489582	2/14/1994	10/3/1995 1923243
071949-4801	United States of America	BIOSITE (Stylized)	Registered	Biosite Inc	74/260208	3/30/1992	9/28/1993 1794618
071949-4802	United States of America	BIOSITE (Stylized)	Registered	Biosite Inc	74/260475	3/30/1992	10/5/1993 1795657
071949-4819	United States of America	BIOSITE and Design	Registered	Biosite Inc	76/634473	3/28/2005	10/10/2006 3152581
071949-5101	United States of America	TRIAGE	Registered	Biosite Inc	74/525008	5/16/1994	2/6/1996 1954150
071949-5202	United States of America	TpP Stylized	Registered	Biosite Inc	75/172105	9/26/1996	1/14/2003 2673476
071949-6401	United States of America	EXPRESS TEST	Registered	Biosite Inc	75/075619	3/20/1996	12/1/1998 2207727
071949-6402	United States of America	EXPRESS TEST and Design	Registered	Biosite Inc	75/099733	5/2/1996	9/21/1999 2279640
071949-8101	United States of America	CARDIO PROFILER	Registered	Biosite Inc	78/178159	10/24/2002	6/7/2005 2960760

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

The following Supplemental Schedules (the “*Schedules*”) of the Grantors with respect to that certain Second Lien Intellectual Property Security Agreement among the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the “*Agreement*”) are being delivered pursuant to Section 7 of Schedule 7.15 to the Second Lien Credit Agreement by and among the Borrower, Holdings, the Lenders party thereto, General Electric Capital Corporation, as Administrative Agent, UBS Securities LLC, as Syndication Agent, Joint Lead Arranger and Sole Bookrunner, and GE Capital Markets, Inc., as Joint Lead Arranger dated as of June 26, 2007 . Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement. The Schedules give effect to, and contain data relating to, the acquisition by a wholly-owned subsidiary of Inverness Medical Innovations, Inc. of the capital stock of Quality Assured Services, Inc., only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Patents - None

SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

Trademarks - Quality Assured Services, Inc.

Name of Mark	Serial Number	Status
Cafe PTINR	78857466	Approved 04-10-2007
QAS	78857429	Pending Approval (Published for opposition)
INRCare	78810066	Pending Approval (Published for opposition)
Town Hall Meeting	78867671	Pending Approval (Published for opposition)
The Best Way to Test	77030923	Pending Approval
IN-Range	78866759	Abandoned
Vitamin K Registry	78866731	Abandoned
PTINR.COM	78857424	Allowed for Registration on Supplemental Register
Vitamin K Food Diary	78866740	Allowed for Registration on Supplemental Register

**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of August [15], 2007, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

DIAMICS, INC.

By:

Name: Peter Gombrich

Title: Chairman and CEO

[SIGNATURE PAGE TO COUNTERPART TO IP SECURITY AGREEMENT – DIAMICS, INC. – SECOND LIEN]
LEGAL_US_E # 76026077

TRADEMARK
REEL: 003641 FRAME: 0693

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Diamics, Inc. as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of August 15, 2007 and give effect to, and contain data relating to, the acquisition by a wholly-owned subsidiary of Inverness Medical Innovations, Inc. of certain of the capital stock of Diamics, Inc. only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.


SCHEDULE 1A
TO
SECOND
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

Copyrights - None

SCHEDULE 1B
TO
SECOND
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

See attached list of patents.

CERVICAL ANALYSIS SYSTEM AND COLLECTOR PATENTS



CERVICAL ANALYSIS SYSTEM AND COLLECTOR PATENTS

New claim added to U.S. system application

A system comprising:
means for collecting and maintaining the spatial orientation
of cervical cell clusters;
means for transferring a sample of the collected cell
clusters onto a slide while maintaining the spatial orientation of
the transferred sample and without changing or destroying the
morphological aspects of the transferred sample; and
a container with preservative for receiving the remaining
collected cervical cell clusters, the preservative maintaining the
morphological aspects of the remaining cell clusters and
their antigenicity.

ASSAY FOR INDICATING A CELL TISSUE CONDITION PATENT

Provisional application
60/885146
Filed Jan. 16, 2007

POINT OF CARE CERVICAL SCREENING SYSTEM

Provisional application
60/939533
Filed May 22, 2007

SCHEDULE 1C
TO
~~SECOND~~ LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

See attached list of trademarks.

TRADEMARKS

CYSAVE
SN 78/748299
Filed 11/7/05
Stat: Allowed

CYSRAY
SN 78/748247
Filed 11/7/05
Stat: Allowed

C-MAP
SN 78/799137
Filed 1/25/06
Stat: Allowed

CER-COL
SN 78/799144
Filed 1/25/06
Stat: Allowed

**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of October 12, 2007, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedule IA, IB, and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedule IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

CHOLESTECH CORPORATION

By:

Name: DAVID TETEL

Title: VICE PRESIDENT FINANCE

[SIGNATURE PAGE TO COUNTERPART TO IP SECURITY AGREEMENT – CHOLESTECH CORPORATION – SECOND LIEN]
LEGAL_US_E # 76561878

TRADEMARK
REEL: 003641 FRAME: 0702

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Cholestech Corporation as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of October 12 2007 and give effect to, and contain data relating to, the acquisition by Inverness Medical Innovations, Inc. of certain of the capital stock of Cholestech Corporation only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None

SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

Issued Patents:

PATENT NUMBER	TITLE	ISSUE DATE	EXPIRATION DATE	COUNTRIES GRANTED
US 5,110,72	Multi-Analyte Assay Device	5/05/92	5/05/09	U.S.
US 5,114,350	Controlled-Volume Assay Apparatus	5/19/92	5/19/09	U.S.
US 5,156,964	Assay Device and Method using a Signal Modulating Compound	10/20/9	10/20/09	U.S.
US 5,171,688	Self-Correcting Assay Device	12/15/92	12/15/09	U.S.
US 5,213,965	Solid-Phase Precipitation Assay Device	5/25/93	5/25/10	U.S., PCT, Japan, Korea, Australia
US 5,213,964	High-Density Lipoprotein Solid-Phase Precipitation Assay Method	5/25/93	5/25/10	U.S. PCT, Japan, Korea, Australia
US 5,316,916	HDL Solid Phase Assay Device	5/31/94	5/31/11	U.S. PCT, Japan, Korea, Australia
US 5,451,370	High Density Lipoprotein Assay Device and Method	4/19/05	4/19/22	U.S., PCT, Japan
US 7,220,595	Automated Immunoassay Cassette,	5-22-07		US

Pending Applications:

PATENT APPLICATION NUMBER	TITLE	FILING DATE
20040235182	Adhered Membranes Retaining Porosity and Biological Activity	4/02/03
Unpublished	Novel Algorithm to measure LDL Cholesterol	1/07
20050221502	Assay System and Method for Direct Measurement of LDL Cholesterol	4/02/04
20030224471	High-Density Lipoprotein Assay Device and Method	4/9/02

SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

Trademarks:

TRADEMARK	COUNTRY	REGISTRATION NUMBER
Cholestech	Argentina	1,614,070
Cholestech	Australia	A589031
Cholestech	Benelux	526249
Cholestech	Brazil	818323957
Cholestech	Canada	430,654
Cholestech	France	92 443 221
Cholestech	Germany	2 066 360
Cholestech	Italy	00644845
Cholestech	Japan	3093467
Cholestech	Mexico	510537
Cholestech	Spain	1733685
Cholestech	Switzerland	531,830
Cholestech	United Kingdom	B1517230
Cholestech	United States of America	1,767,348
Cholestech GDX	Australia	936842
Cholestech GDX	European Community	296017
Cholestech GDX	Republic of Korea	579229
Cholestech GDX	Taiwan	91051354
Cholestech GDX	Taiwan	1066087
Cholestech GDX	United States of America	2,882,423
Cholestech L D X	Mexico	510536
Cholestech L D X	United States of America	1,705,798
Cholestech L*D*X	Argentina	1,643,621
Cholestech L*D*X	Brazil	818323949
Cholestech L.D.X	Benelux	526250
Cholestech L.D.X	France	92443220
Cholestech L.D.X	Germany	2,059,006
Cholestech L.D.X	Spain	1730024
Cholestech LDX	Italy	644846
Design (Cholestech Logo)	United States of America	1,799,242